Literature DB >> 22430284

[Cardiovascular effects of incretin-based therapies].

M Lehrke1, N Marx.   

Abstract

Pharmacological modulation of the glucagon-like peptide-1 (GLP-1) system has emerged as a new therapeutic option for treatment of diabetes mellitus. In addition to the glucose lowering potential GLP-1 was found to have a variety of cardioprotective effects. GLP-1 reduced the size of myocardial infarction during acute ischemia by activation of prosurvival pathways including PI3-kinase, Akt und ERK1/2. In addition, GLP-1 prevented atherosclerotic lesion formation in experimental models and improved endothelial function while acting anti-inflammatory. Furthermore GLP-1 was found to improve chronic heart failure by increasing insulin independent cellular glucose transport. Consequently GLP-1 based therapies might reduce cardiovascular events in diabetic patients which is currently evaluated in clinical endpoint studies.

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22430284     DOI： 10.1007/s00059-012-3599-8

Source DB:  PubMed          Journal:  Herz        ISSN： 0340-9937            Impact factor:   1.443


  85 in total

1.  Antiapoptotic effects of GLP-1 in murine HL-1 cardiomyocytes.

Authors:  Susana Ravassa; Amaia Zudaire; Richard D Carr; Javier Díez
Journal:  Am J Physiol Heart Circ Physiol       Date:  2011-01-28       Impact factor: 4.733

2.  Glucagon-like peptide-1 infusion improves left ventricular ejection fraction and functional status in patients with chronic heart failure.

Authors:  George G Sokos; Lazaros A Nikolaidis; Sunil Mankad; Dariush Elahi; Richard P Shannon
Journal:  J Card Fail       Date:  2006-12       Impact factor: 5.712

3.  Glucagon-like peptide 1 prevents reactive oxygen species-induced endothelial cell senescence through the activation of protein kinase A.

Authors:  Hisko Oeseburg; Rudolf A de Boer; Hendrik Buikema; Pim van der Harst; Wiek H van Gilst; Herman H W Silljé
Journal:  Arterioscler Thromb Vasc Biol       Date:  2010-05-06       Impact factor: 8.311

4.  Effects of GLP-1-(7-36)NH2, GLP-1-(7-37), and GLP-1- (9-36)NH2 on intravenous glucose tolerance and glucose-induced insulin secretion in healthy humans.

Authors:  Torsten P Vahl; Breay W Paty; Bradley D Fuller; Ronald L Prigeon; David A D'Alessio
Journal:  J Clin Endocrinol Metab       Date:  2003-04       Impact factor: 5.958

5.  GLP-1-(9-36) amide reduces blood glucose in anesthetized pigs by a mechanism that does not involve insulin secretion.

Authors:  Carolyn F Deacon; Astrid Plamboeck; Søren Møller; Jens J Holst
Journal:  Am J Physiol Endocrinol Metab       Date:  2002-04       Impact factor: 4.310

6.  Effects of centrally or systemically injected glucagon-like peptide-1 (7-36) amide on release of neurohypophysial hormones and blood pressure in the rat.

Authors:  E Bojanowska; B Stempniak
Journal:  Regul Pept       Date:  2000-07-28

7.  Cardiovascular and metabolic effects of 48-h glucagon-like peptide-1 infusion in compensated chronic patients with heart failure.

Authors:  Mads Halbirk; Helene Nørrelund; Niels Møller; Jens Juul Holst; Ole Schmitz; Roni Nielsen; Jens Erik Nielsen-Kudsk; Søren Steen Nielsen; Torsten Toftegaard Nielsen; Hans Eiskjaer; Hans Erik Bøtker; Henrik Wiggers
Journal:  Am J Physiol Heart Circ Physiol       Date:  2010-01-15       Impact factor: 4.733

8.  GLP-1 and related peptides cause concentration-dependent relaxation of rat aorta through a pathway involving KATP and cAMP.

Authors:  Brian D Green; Katharine V Hand; Janette E Dougan; Bronagh M McDonnell; Roslyn S Cassidy; David J Grieve
Journal:  Arch Biochem Biophys       Date:  2008-08-07       Impact factor: 4.013

9.  GLP-1 mediates antiapoptotic effect by phosphorylating Bad through a beta-arrestin 1-mediated ERK1/2 activation in pancreatic beta-cells.

Authors:  Julie Quoyer; Christine Longuet; Christophe Broca; Nathalie Linck; Safia Costes; Elodie Varin; Joël Bockaert; Gyslaine Bertrand; Stéphane Dalle
Journal:  J Biol Chem       Date:  2009-11-13       Impact factor: 5.157

10.  Genetic deletion or pharmacological inhibition of dipeptidyl peptidase-4 improves cardiovascular outcomes after myocardial infarction in mice.

Authors:  Meghan Sauvé; Kiwon Ban; M Abdul Momen; Yu-Qing Zhou; R Mark Henkelman; Mansoor Husain; Daniel J Drucker
Journal:  Diabetes       Date:  2010-01-22       Impact factor: 9.461
View more
  1 in total

Review 1.  [Diabetology as an interdisciplinary challenge].

Authors:  D Müller-Wieland; N Marx
Journal:  Internist (Berl)       Date:  2017-04       Impact factor: 0.743
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.